X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/ascletis-announces-strategic-decisions-on-fxr-agonist-asc42-302107029.html
https://endpts.com/ascletis-pharma-scraps-liver-disease-program-another-reverse-merger/
https://www.prnewswire.com/news-releases/ascletis-announces-poster-presentation-of-phase-ii-study-final-results-of-fasn-inhibitor-asc40-for-treatment-of-acne-at-2024-aad-annual-meeting-302084734.html
https://endpts.com/ascletis-gannex-reports-positive-interim-phii-nash-data-after-scrapping-previous-mid-stage-rd-plans/
https://www.prnewswire.com/news-releases/ascletis-announces-initiation-of-phase-iii-clinical-trial-of-asc40-denifanstat-for-treatment-of-acne-302005533.html
https://www.prnewswire.com/news-releases/ascletis-announces-poster-presentations-at-aasld-annual-meeting-2023-including-a-late-breaking-abstract-of-interim-results-from-phase-iib-expansion-cohort-of-asc22-for-functional-cure-of-chb-301985282.html
https://www.prnewswire.com/news-releases/ascletis-announces-positive-interim-data-from-the-phase-iib-expansion-cohort-of-asc22-envafolimab-for-chronic-hepatitis-b-functional-cure-301941562.html
https://www.prnewswire.com/news-releases/ascletis-announces-completion-of-enrollment-of-120-patients-in-the-phase-iii-clinical-trial-of-fasn-inhibitor-asc40-combined-with-bevacizumab-for-treatment-of-recurrent-glioblastoma-301937564.html
https://www.prnewswire.com/news-releases/clinical-results-of-asc22-envafolimab-in-combination-with-chidamide-for-functional-cure-of-hiv-infection-presented-at-the-12th-ias-conference-on-hiv-science-301884101.html
https://www.prnewswire.com/news-releases/ascletis-announces-china-nmpa-approval-of-conducting-a-phase-iia-clinical-trial-for-asc10-to-treat-respiratory-syncytial-virus-infection-301817999.html
Market Place
Share 
